ALPHAMAB ONCOLO.DL-000002
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors… Read more
Market Cap & Net Worth: ALPHAMAB ONCOLO.DL-000002 (3NK)
ALPHAMAB ONCOLO.DL-000002 (F:3NK) has a market capitalization of $934.56 Million (€910.46 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #10637 globally and #1127 in its home market, demonstrating a 9.30% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ALPHAMAB ONCOLO.DL-000002's stock price €0.94 by its total outstanding shares 968574697 (968.57 Million).
ALPHAMAB ONCOLO.DL-000002 Market Cap History: 2019 to 2026
ALPHAMAB ONCOLO.DL-000002's market capitalization history from 2019 to 2026. Data shows change from $1.61 Billion to $934.56 Million (-8.53% CAGR).
ALPHAMAB ONCOLO.DL-000002 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ALPHAMAB ONCOLO.DL-000002's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 3NK by Market Capitalization
Companies near ALPHAMAB ONCOLO.DL-000002 in the global market cap rankings as of March 18, 2026.
Key companies related to ALPHAMAB ONCOLO.DL-000002 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ALPHAMAB ONCOLO.DL-000002 Historical Marketcap From 2019 to 2026
Between 2019 and today, ALPHAMAB ONCOLO.DL-000002's market cap moved from $1.61 Billion to $ 934.56 Million, with a yearly change of -8.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €934.56 Million | -10.48% |
| 2025 | €1.04 Billion | +138.64% |
| 2024 | €437.45 Million | -41.33% |
| 2023 | €745.66 Million | -41.86% |
| 2022 | €1.28 Billion | -9.15% |
| 2021 | €1.41 Billion | -18.39% |
| 2020 | €1.73 Billion | +7.21% |
| 2019 | €1.61 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of ALPHAMAB ONCOLO.DL-000002 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $934.56 Million USD |
| MoneyControl | $934.56 Million USD |
| MarketWatch | $934.56 Million USD |
| marketcap.company | $934.56 Million USD |
| Reuters | $934.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.